Study summary

A cardiac myosin inhibitor improved exercise capacity in obstructive HCM

SEQUOIA-HCM trial · 282 people, phase 3 · Published May 2024, New England Journal of Medicine; FDA approved December 2025

1.8ml/kg/min gain in peak oxygen uptake, vs 0.0 with placebo

What was tested

Aficamten, a pill that calms the overactive heart muscle by inhibiting cardiac myosin, against placebo, for symptomatic obstructive hypertrophic cardiomyopathy.

What they found

Peak oxygen uptake rose 1.8 ml/kg/min vs no change with placebo.
Symptoms, NYHA class and outflow-tract obstruction all improved.

What it means

The second cardiac myosin inhibitor approved, after mavacamten.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.